Abstract
In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial, tafamidis significantly reduced all-cause mortality and cardiovascular-related hospit......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
